FluLaval

Overview

influenza vaccine

vaccine

• non-live vaccine

Avoid/Use Alternative

• interferon gamma 1b
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

interferon gamma 1b

1 interaction

Avoid/Use Alternative

influenza vaccine + interferon gamma 1b

avoid combo: combo may result in amplified immune response (immunomodulatory effects)

Monitor/Modify Tx

• abatacept
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

abatacept

1 interaction

Monitor/Modify Tx

influenza vaccine + abatacept

if possible, vaccinate at least 2wk before starting abatacept tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abemaciclib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

abemaciclib

1 interaction

Monitor/Modify Tx

influenza vaccine + abemaciclib

if possible, vaccinate at least 2wk before starting abemaciclib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abrocitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

abrocitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + abrocitinib

if possible, vaccinate at least 2wk before starting abrocitinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• acalabrutinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

acalabrutinib

1 interaction

Monitor/Modify Tx

influenza vaccine + acalabrutinib

if possible, vaccinate at least 2wk before starting acalabrutinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• adalimumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

adalimumab

1 interaction

Monitor/Modify Tx

influenza vaccine + adalimumab

if possible, vaccinate at least 2wk before starting adalimumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ado-trastuzumab emtansine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

influenza vaccine + ado-trastuzumab emtansine

if possible, vaccinate at least 2wk before starting ado-trastuzumab emtansine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• afamitresgene autoleucel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

afamitresgene autoleucel

1 interaction

Monitor/Modify Tx

influenza vaccine + afamitresgene autoleucel

if possible, vaccinate at least 2wk before starting afamitresgene autoleucel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• aldesleukin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

aldesleukin

1 interaction

Monitor/Modify Tx

influenza vaccine + aldesleukin

if possible, vaccinate at least 2wk before starting aldesleukin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• alemtuzumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

alemtuzumab

1 interaction

Monitor/Modify Tx

influenza vaccine + alemtuzumab

if possible, vaccinate at least 2wk before starting alemtuzumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• amivantamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

amivantamab

1 interaction

Monitor/Modify Tx

influenza vaccine + amivantamab

if possible, vaccinate at least 2wk before starting amivantamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anakinra
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

anakinra

1 interaction

Monitor/Modify Tx

influenza vaccine + anakinra

if possible, vaccinate at least 2wk before starting anakinra tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anifrolumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

anifrolumab

1 interaction

Monitor/Modify Tx

influenza vaccine + anifrolumab

if possible, vaccinate at least 2wk before starting anifrolumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

influenza vaccine + anti-thymocyte globulin

if possible, vaccinate at least 2wk before starting anti-thymocyte globulin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• asciminib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

asciminib

1 interaction

Monitor/Modify Tx

influenza vaccine + asciminib

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atezolizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

atezolizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + atezolizumab

if possible, vaccinate at least 2wk before starting atezolizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atidarsagene autotemcel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

influenza vaccine + atidarsagene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• avelumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

avelumab

1 interaction

Monitor/Modify Tx

influenza vaccine + avelumab

if possible, vaccinate at least 2wk before starting avelumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• avutometinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

avutometinib

1 interaction

Monitor/Modify Tx

influenza vaccine + avutometinib

if possible, vaccinate at least 2wk before starting avutometinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• axicabtagene ciloleucel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

axicabtagene ciloleucel

1 interaction

Monitor/Modify Tx

influenza vaccine + axicabtagene ciloleucel

if possible, vaccinate at least 2wk before starting axicabtagene ciloleucel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azacitidine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

azacitidine

1 interaction

Monitor/Modify Tx

influenza vaccine + azacitidine

if possible, vaccinate at least 2wk before starting azacitidine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azathioprine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

azathioprine

1 interaction

Monitor/Modify Tx

influenza vaccine + azathioprine

if possible, vaccinate at least 2wk before starting azathioprine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• baricitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

baricitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + baricitinib

if possible, vaccinate at least 2wk before starting baricitinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• basiliximab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

basiliximab

1 interaction

Monitor/Modify Tx

influenza vaccine + basiliximab

if possible, vaccinate at least 2wk before starting basiliximab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belantamab mafodotin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

belantamab mafodotin

1 interaction

Monitor/Modify Tx

influenza vaccine + belantamab mafodotin

if possible, vaccinate at least 2wk before starting belantamab mafodotin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belatacept
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

belatacept

1 interaction

Monitor/Modify Tx

influenza vaccine + belatacept

if possible, vaccinate at least 2wk before starting belatacept tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belimumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

belimumab

1 interaction

Monitor/Modify Tx

influenza vaccine + belimumab

if possible, vaccinate at least 2wk before starting belimumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belinostat
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

belinostat

1 interaction

Monitor/Modify Tx

influenza vaccine + belinostat

if possible, vaccinate at least 2wk before starting belinostat tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belzutifan
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

belzutifan

1 interaction

Monitor/Modify Tx

influenza vaccine + belzutifan

if possible, vaccinate at least 2wk before starting belzutifan tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bendamustine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

bendamustine

1 interaction

Monitor/Modify Tx

influenza vaccine + bendamustine

if possible, vaccinate at least 2wk before starting bendamustine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• betamethasone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

betamethasone

1 interaction

Monitor/Modify Tx

influenza vaccine + betamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• bimekizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

bimekizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + bimekizumab

if possible, vaccinate at least 2wk before starting bimekizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• blinatumomab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

blinatumomab

1 interaction

Monitor/Modify Tx

influenza vaccine + blinatumomab

if possible, vaccinate at least 2wk before starting blinatumomab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bortezomib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

bortezomib

1 interaction

Monitor/Modify Tx

influenza vaccine + bortezomib

if possible, vaccinate at least 2wk before starting bortezomib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brentuximab vedotin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

influenza vaccine + brentuximab vedotin

if possible, vaccinate at least 2wk before starting brentuximab vedotin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brexucabtagene autoleucel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

brexucabtagene autoleucel

1 interaction

Monitor/Modify Tx

influenza vaccine + brexucabtagene autoleucel

if possible, vaccinate at least 2wk before starting brexucabtagene autoleucel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brodalumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

brodalumab

1 interaction

Monitor/Modify Tx

influenza vaccine + brodalumab

if possible, vaccinate at least 2wk before starting brodalumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

budesonide

1 interaction

Monitor/Modify Tx

influenza vaccine + budesonide

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide rectal
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

budesonide rectal

1 interaction

Monitor/Modify Tx

influenza vaccine + budesonide rectal

consider vaccinating at least 2wk before budesonide rectal use: combo may result in inadequate vaccine response (immunosuppressive effects)

• busulfan
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

busulfan

1 interaction

Monitor/Modify Tx

influenza vaccine + busulfan

if possible, vaccinate at least 2wk before starting busulfan tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cabazitaxel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cabazitaxel

1 interaction

Monitor/Modify Tx

influenza vaccine + cabazitaxel

if possible, vaccinate at least 2wk before starting cabazitaxel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• canakinumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

canakinumab

1 interaction

Monitor/Modify Tx

influenza vaccine + canakinumab

if possible, vaccinate at least 2wk before starting canakinumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• capecitabine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

capecitabine

1 interaction

Monitor/Modify Tx

influenza vaccine + capecitabine

if possible, vaccinate at least 2wk before starting capecitabine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• capmatinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

capmatinib

1 interaction

Monitor/Modify Tx

influenza vaccine + capmatinib

if possible, vaccinate at least 2wk before starting capmatinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carboplatin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

carboplatin

1 interaction

Monitor/Modify Tx

influenza vaccine + carboplatin

if possible, vaccinate at least 2wk before starting carboplatin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carfilzomib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

carfilzomib

1 interaction

Monitor/Modify Tx

influenza vaccine + carfilzomib

if possible, vaccinate at least 2wk before starting carfilzomib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carmustine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

carmustine

1 interaction

Monitor/Modify Tx

influenza vaccine + carmustine

if possible, vaccinate at least 2wk before starting carmustine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cemiplimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cemiplimab

1 interaction

Monitor/Modify Tx

influenza vaccine + cemiplimab

if possible, vaccinate at least 2wk before starting cemiplimab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• certolizumab pegol
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

certolizumab pegol

1 interaction

Monitor/Modify Tx

influenza vaccine + certolizumab pegol

if possible, vaccinate at least 2wk before starting certolizumab pegol tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chlorambucil
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

chlorambucil

1 interaction

Monitor/Modify Tx

influenza vaccine + chlorambucil

if possible, vaccinate at least 2wk before starting chlorambucil tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ciltacabtagene autoleucel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ciltacabtagene autoleucel

1 interaction

Monitor/Modify Tx

influenza vaccine + ciltacabtagene autoleucel

if possible, vaccinate at least 2wk before starting ciltacabtagene autoleucel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cisplatin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cisplatin

1 interaction

Monitor/Modify Tx

influenza vaccine + cisplatin

if possible, vaccinate at least 2wk before starting cisplatin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine injection
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cladribine injection

1 interaction

Monitor/Modify Tx

influenza vaccine + cladribine injection

if possible, vaccinate at least 2wk before starting cladribine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine oral
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cladribine oral

1 interaction

Monitor/Modify Tx

influenza vaccine + cladribine oral

if possible, vaccinate at least 2wk before starting cladribine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• clofarabine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

clofarabine

1 interaction

Monitor/Modify Tx

influenza vaccine + clofarabine

if possible, vaccinate at least 2wk before starting clofarabine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• copanlisib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

copanlisib

1 interaction

Monitor/Modify Tx

influenza vaccine + copanlisib

if possible, vaccinate at least 2wk before starting copanlisib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• corticotropin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

corticotropin

1 interaction

Monitor/Modify Tx

influenza vaccine + corticotropin

if possible, vaccinate at least 2wk before starting corticotropin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cortisone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cortisone

1 interaction

Monitor/Modify Tx

influenza vaccine + cortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• cosibelimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cosibelimab

1 interaction

Monitor/Modify Tx

influenza vaccine + cosibelimab

if possible, vaccinate at least 2wk before starting cosibelimab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclophosphamide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

influenza vaccine + cyclophosphamide

if possible, vaccinate at least 2wk before starting cyclophosphamide tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclosporine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cyclosporine

1 interaction

Monitor/Modify Tx

influenza vaccine + cyclosporine

if possible, vaccinate at least 2wk before starting cyclosporine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cytarabine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

cytarabine

1 interaction

Monitor/Modify Tx

influenza vaccine + cytarabine

if possible, vaccinate at least 2wk before cytarabine start; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dactinomycin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

dactinomycin

1 interaction

Monitor/Modify Tx

influenza vaccine + dactinomycin

if possible, vaccinate at least 2wk before starting dactinomycin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daratumumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

daratumumab

1 interaction

Monitor/Modify Tx

influenza vaccine + daratumumab

if possible, vaccinate at least 2wk before starting daratumumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dasatinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

dasatinib

1 interaction

Monitor/Modify Tx

influenza vaccine + dasatinib

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daunorubicin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

daunorubicin

1 interaction

Monitor/Modify Tx

influenza vaccine + daunorubicin

if possible, vaccinate at least 2wk before daunorubicin start; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• decitabine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

decitabine

1 interaction

Monitor/Modify Tx

influenza vaccine + decitabine

if possible, vaccinate at least 2wk before starting decitabine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• defactinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

defactinib

1 interaction

Monitor/Modify Tx

influenza vaccine + defactinib

if possible, vaccinate at least 2wk before starting defactinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deflazacort
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

deflazacort

1 interaction

Monitor/Modify Tx

influenza vaccine + deflazacort

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• delgocitinib topical
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

delgocitinib topical

1 interaction

Monitor/Modify Tx

influenza vaccine + delgocitinib topical

if possible, vaccinate at least 2wk before starting delgocitinib topical tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deucravacitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

deucravacitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + deucravacitinib

if possible, vaccinate at least 2wk before starting deucravacitinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deuruxolitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + deuruxolitinib

if possible, vaccinate at least 2wk before starting deuruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dexamethasone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

dexamethasone

1 interaction

Monitor/Modify Tx

influenza vaccine + dexamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• dimethyl fumarate
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

influenza vaccine + dimethyl fumarate

if possible, vaccinate at least 2wk before starting dimethyl fumarate tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dinutuximab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

dinutuximab

1 interaction

Monitor/Modify Tx

influenza vaccine + dinutuximab

if possible, vaccinate at least 2wk before starting dinutuximab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diroximel fumarate
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

influenza vaccine + diroximel fumarate

if possible, vaccinate at least 2wk before starting diroximel fumarate tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• docetaxel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

docetaxel

1 interaction

Monitor/Modify Tx

influenza vaccine + docetaxel

if possible, vaccinate at least 2wk before starting docetaxel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dordaviprone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

dordaviprone

1 interaction

Monitor/Modify Tx

influenza vaccine + dordaviprone

if possible, vaccinate at least 2wk before starting dordaviprone tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dostarlimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

dostarlimab

1 interaction

Monitor/Modify Tx

influenza vaccine + dostarlimab

if possible, vaccinate at least 2wk before starting dostarlimab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• doxorubicin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

doxorubicin

1 interaction

Monitor/Modify Tx

influenza vaccine + doxorubicin

if possible, vaccinate at least 2wk before starting doxorubicin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dupilumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

dupilumab

1 interaction

Monitor/Modify Tx

influenza vaccine + dupilumab

if possible, vaccinate at least 2wk before starting dupilumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• durvalumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

durvalumab

1 interaction

Monitor/Modify Tx

influenza vaccine + durvalumab

if possible, vaccinate at least 2wk before starting durvalumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• duvelisib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

duvelisib

1 interaction

Monitor/Modify Tx

influenza vaccine + duvelisib

if possible, vaccinate at least 2wk before starting duvelisib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• efgartigimod alfa
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

efgartigimod alfa

1 interaction

Monitor/Modify Tx

influenza vaccine + efgartigimod alfa

if possible, vaccinate at least 2wk before starting efgartigimod alfa tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elivaldogene autotemcel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

influenza vaccine + elivaldogene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• elotuzumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

elotuzumab

1 interaction

Monitor/Modify Tx

influenza vaccine + elotuzumab

if possible, vaccinate at least 2wk before starting elotuzumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elranatamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

elranatamab

1 interaction

Monitor/Modify Tx

influenza vaccine + elranatamab

if possible, vaccinate at least 2wk before starting elranatamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• emapalumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

emapalumab

1 interaction

Monitor/Modify Tx

influenza vaccine + emapalumab

if possible, vaccinate at least 2wk before starting emapalumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epcoritamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

epcoritamab

1 interaction

Monitor/Modify Tx

influenza vaccine + epcoritamab

if possible, vaccinate at least 2wk before starting epcoritamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epirubicin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

epirubicin

1 interaction

Monitor/Modify Tx

influenza vaccine + epirubicin

if possible, vaccinate at least 2wk before starting epirubicin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• erdafitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

erdafitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + erdafitinib

if possible, vaccinate at least 2wk before starting erdafitinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• eribulin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

eribulin

1 interaction

Monitor/Modify Tx

influenza vaccine + eribulin

if possible, vaccinate at least 2wk before starting eribulin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etanercept
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

etanercept

1 interaction

Monitor/Modify Tx

influenza vaccine + etanercept

if possible, vaccinate at least 2wk before starting etanercept tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etoposide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

etoposide

1 interaction

Monitor/Modify Tx

influenza vaccine + etoposide

if possible, vaccinate at least 2wk before etoposide start; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etrasimod
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

etrasimod

1 interaction

Monitor/Modify Tx

influenza vaccine + etrasimod

if possible, vaccinate at least 2wk before starting etrasimod tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etuvetidigene autotemcel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

influenza vaccine + etuvetidigene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• everolimus
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

everolimus

1 interaction

Monitor/Modify Tx

influenza vaccine + everolimus

if possible, vaccinate at least 2wk before starting everolimus tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fam-trastuzumab deruxtecan
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

fam-trastuzumab deruxtecan

1 interaction

Monitor/Modify Tx

influenza vaccine + fam-trastuzumab deruxtecan

if possible, vaccinate at least 2wk before starting fam-trastuzumab deruxtecan tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fingolimod
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

fingolimod

1 interaction

Monitor/Modify Tx

influenza vaccine + fingolimod

if possible, vaccinate at least 2wk before starting fingolimod tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• floxuridine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

floxuridine

1 interaction

Monitor/Modify Tx

influenza vaccine + floxuridine

if possible, vaccinate at least 2wk before starting floxuridine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludarabine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

fludarabine

1 interaction

Monitor/Modify Tx

influenza vaccine + fludarabine

if possible, vaccinate at least 2wk before starting fludarabine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludrocortisone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

fludrocortisone

1 interaction

Monitor/Modify Tx

influenza vaccine + fludrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• fluorouracil
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

fluorouracil

1 interaction

Monitor/Modify Tx

influenza vaccine + fluorouracil

if possible, vaccinate at least 2wk before fluorouracil start; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fruquintinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

fruquintinib

1 interaction

Monitor/Modify Tx

influenza vaccine + fruquintinib

if possible, vaccinate at least 2wk before starting fruquintinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• futibatinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

futibatinib

1 interaction

Monitor/Modify Tx

influenza vaccine + futibatinib

if possible, vaccinate at least 2wk before starting futibatinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemcitabine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

gemcitabine

1 interaction

Monitor/Modify Tx

influenza vaccine + gemcitabine

if possible, vaccinate at least 2wk before starting gemcitabine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemtuzumab ozogamicin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

influenza vaccine + gemtuzumab ozogamicin

if possible, vaccinate at least 2wk before starting gemtuzumab ozogamicin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• glofitamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

glofitamab

1 interaction

Monitor/Modify Tx

influenza vaccine + glofitamab

if possible, vaccinate at least 2wk before starting glofitamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• golimumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

golimumab

1 interaction

Monitor/Modify Tx

influenza vaccine + golimumab

if possible, vaccinate at least 2wk before starting golimumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• guselkumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

guselkumab

1 interaction

Monitor/Modify Tx

influenza vaccine + guselkumab

if possible, vaccinate at least 2wk before starting guselkumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydrocortisone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

hydrocortisone

1 interaction

Monitor/Modify Tx

influenza vaccine + hydrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydroxyurea
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

hydroxyurea

1 interaction

Monitor/Modify Tx

influenza vaccine + hydroxyurea

if possible, vaccinate at least 2wk before starting hydroxyurea tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibritumomab tiuxetan
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ibritumomab tiuxetan

1 interaction

Monitor/Modify Tx

influenza vaccine + ibritumomab tiuxetan

if possible, vaccinate at least 2wk before starting ibritumomab tiuxetan tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibrutinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ibrutinib

1 interaction

Monitor/Modify Tx

influenza vaccine + ibrutinib

if possible, vaccinate at least 2wk before starting ibrutinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• icotrokinra
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

icotrokinra

1 interaction

Monitor/Modify Tx

influenza vaccine + icotrokinra

if possible, vaccinate at least 2wk before icotrokinra start; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idarubicin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

idarubicin

1 interaction

Monitor/Modify Tx

influenza vaccine + idarubicin

if possible, vaccinate at least 2wk before starting idarubicin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idecabtagene vicleucel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

idecabtagene vicleucel

1 interaction

Monitor/Modify Tx

influenza vaccine + idecabtagene vicleucel

if possible, vaccinate at least 2wk before starting idecabtagene vicleucel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idelalisib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

idelalisib

1 interaction

Monitor/Modify Tx

influenza vaccine + idelalisib

if possible, vaccinate at least 2wk before starting idelalisib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ifosfamide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ifosfamide

1 interaction

Monitor/Modify Tx

influenza vaccine + ifosfamide

if possible, vaccinate at least 2wk before starting ifosfamide tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• imatinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

imatinib

1 interaction

Monitor/Modify Tx

influenza vaccine + imatinib

if possible, vaccinate at least 2wk before starting imatinib; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inebilizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

inebilizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + inebilizumab

if possible, vaccinate at least 4wk before starting inebilizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• infliximab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

infliximab

1 interaction

Monitor/Modify Tx

influenza vaccine + infliximab

if possible, vaccinate at least 2wk before starting infliximab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inotuzumab ozogamicin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

influenza vaccine + inotuzumab ozogamicin

if possible, vaccinate at least 2wk before starting inotuzumab ozogamicin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ipilimumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ipilimumab

1 interaction

Monitor/Modify Tx

influenza vaccine + ipilimumab

if possible, vaccinate at least 2wk before starting ipilimumab; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• irinotecan
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

irinotecan

1 interaction

Monitor/Modify Tx

influenza vaccine + irinotecan

if possible, vaccinate at least 2wk before starting irinotecan tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• isatuximab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

isatuximab

1 interaction

Monitor/Modify Tx

influenza vaccine + isatuximab

if possible, vaccinate at least 2wk before starting isatuximab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixabepilone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ixabepilone

1 interaction

Monitor/Modify Tx

influenza vaccine + ixabepilone

if possible, vaccinate at least 2wk before starting ixabepilone tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixekizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ixekizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + ixekizumab

if possible, vaccinate at least 2wk before starting ixekizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lazertinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

lazertinib

1 interaction

Monitor/Modify Tx

influenza vaccine + lazertinib

if possible, vaccinate at least 2wk before starting lazertinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lebrikizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

lebrikizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + lebrikizumab

if possible, vaccinate at least 2wk before starting lebrikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• leflunomide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

leflunomide

1 interaction

Monitor/Modify Tx

influenza vaccine + leflunomide

if possible, vaccinate at least 2wk before starting leflunomide tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lenalidomide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

lenalidomide

1 interaction

Monitor/Modify Tx

influenza vaccine + lenalidomide

if possible, vaccinate at least 2wk before starting lenalidomide tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• linvoseltamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

linvoseltamab

1 interaction

Monitor/Modify Tx

influenza vaccine + linvoseltamab

if possible, vaccinate at least 2wk before starting linvoseltamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lisocabtagene maraleucel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

lisocabtagene maraleucel

1 interaction

Monitor/Modify Tx

influenza vaccine + lisocabtagene maraleucel

if possible, vaccinate at least 2wk before starting lisocabtagene maraleucel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lomustine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

lomustine

1 interaction

Monitor/Modify Tx

influenza vaccine + lomustine

if possible, vaccinate at least 2wk before starting lomustine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• loncastuximab tesirine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

loncastuximab tesirine

1 interaction

Monitor/Modify Tx

influenza vaccine + loncastuximab tesirine

if possible, vaccinate at least 2wk before starting loncastuximab tesirine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lurbinectedin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

lurbinectedin

1 interaction

Monitor/Modify Tx

influenza vaccine + lurbinectedin

if possible, vaccinate at least 2wk before starting lurbinectedin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

influenza vaccine + lymphocyte immune globulin, anti-thymocyte globulin

if possible, vaccinate at least 2wk before starting anti-thymocyte globulin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• margetuximab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

margetuximab

1 interaction

Monitor/Modify Tx

influenza vaccine + margetuximab

if possible, vaccinate at least 2wk before starting margetuximab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• melphalan
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

melphalan

1 interaction

Monitor/Modify Tx

influenza vaccine + melphalan

if possible, vaccinate at least 2wk before starting melphalan tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

mercaptopurine

1 interaction

Monitor/Modify Tx

influenza vaccine + mercaptopurine

if possible, vaccinate at least 2wk before starting mercaptopurine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methotrexate
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

methotrexate

1 interaction

Monitor/Modify Tx

influenza vaccine + methotrexate

if possible, vaccinate at least 2wk before starting methotrexate tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methylprednisolone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

methylprednisolone

1 interaction

Monitor/Modify Tx

influenza vaccine + methylprednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• mirikizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

mirikizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + mirikizumab

if possible, vaccinate at least 2wk before starting mirikizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mitomycin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

mitomycin

1 interaction

Monitor/Modify Tx

influenza vaccine + mitomycin

if possible, vaccinate at least 2wk before starting mitomycin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mitoxantrone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

mitoxantrone

1 interaction

Monitor/Modify Tx

influenza vaccine + mitoxantrone

if possible, vaccinate at least 2wk before starting mitoxantrone tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mogamulizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

mogamulizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + mogamulizumab

if possible, vaccinate at least 2wk before starting mogamulizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• momelotinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

momelotinib

1 interaction

Monitor/Modify Tx

influenza vaccine + momelotinib

if possible, vaccinate at least 2wk before starting momelotinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• monomethyl fumarate
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

influenza vaccine + monomethyl fumarate

if possible, vaccinate at least 2wk before starting monomethyl fumarate tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mosunetuzumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

influenza vaccine + mosunetuzumab

if possible, vaccinate at least 2wk before starting mosunetuzumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolate mofetil
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

influenza vaccine + mycophenolate mofetil

if possible, vaccinate at least 2wk before starting mycophenolate mofetil tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolic acid
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

influenza vaccine + mycophenolic acid

if possible, vaccinate at least 2wk before starting mycophenolic acid tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• natalizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

natalizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + natalizumab

if possible, vaccinate at least 2wk before starting natalizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nelarabine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

nelarabine

1 interaction

Monitor/Modify Tx

influenza vaccine + nelarabine

if possible, vaccinate at least 2wk before starting nelarabine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nemolizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

nemolizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + nemolizumab

if possible, vaccinate at least 2wk before starting nemolizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nilotinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

nilotinib

1 interaction

Monitor/Modify Tx

influenza vaccine + nilotinib

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nipocalimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

nipocalimab

1 interaction

Monitor/Modify Tx

influenza vaccine + nipocalimab

if possible, vaccinate at least 2wk before starting nipocalimab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nivolumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

nivolumab

1 interaction

Monitor/Modify Tx

influenza vaccine + nivolumab

if possible, vaccinate at least 2wk before starting nivolumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obecabtagene autoleucel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

obecabtagene autoleucel

1 interaction

Monitor/Modify Tx

influenza vaccine + obecabtagene autoleucel

if possible, vaccinate at least 2wk before starting obecabtagene autoleucel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obinutuzumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

obinutuzumab

1 interaction

Monitor/Modify Tx

influenza vaccine + obinutuzumab

if possible, vaccinate at least 2wk before starting obinutuzumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ocrelizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ocrelizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + ocrelizumab

if possible, vaccinate at least 2wk before starting ocrelizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ofatumumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ofatumumab

1 interaction

Monitor/Modify Tx

influenza vaccine + ofatumumab

if possible, vaccinate at least 2wk before starting ofatumumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• olaparib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

olaparib

1 interaction

Monitor/Modify Tx

influenza vaccine + olaparib

if possible, vaccinate at least 2wk before starting olaparib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• oxaliplatin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

oxaliplatin

1 interaction

Monitor/Modify Tx

influenza vaccine + oxaliplatin

if possible, vaccinate at least 2wk before starting oxaliplatin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ozanimod
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ozanimod

1 interaction

Monitor/Modify Tx

influenza vaccine + ozanimod

if possible, vaccinate at least 2wk before starting ozanimod tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• paclitaxel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

paclitaxel

1 interaction

Monitor/Modify Tx

influenza vaccine + paclitaxel

if possible, vaccinate at least 2wk before starting paclitaxel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• palbociclib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

palbociclib

1 interaction

Monitor/Modify Tx

influenza vaccine + palbociclib

if possible, vaccinate at least 2wk before starting palbociclib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• peginterferon alfa 2a
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

influenza vaccine + peginterferon alfa 2a

if possible, vaccinate at least 2wk before starting peginterferon alfa 2a tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pembrolizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

pembrolizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + pembrolizumab

if possible, vaccinate at least 2wk before starting pembrolizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pemetrexed
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

pemetrexed

1 interaction

Monitor/Modify Tx

influenza vaccine + pemetrexed

if possible, vaccinate at least 2wk before starting pemetrexed; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• penpulimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

penpulimab

1 interaction

Monitor/Modify Tx

influenza vaccine + penpulimab

if possible, vaccinate at least 2wk before starting penpulimab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pentostatin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

pentostatin

1 interaction

Monitor/Modify Tx

influenza vaccine + pentostatin

if possible, vaccinate at least 2wk before starting pentostatin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pertuzumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

pertuzumab

1 interaction

Monitor/Modify Tx

influenza vaccine + pertuzumab

if possible, vaccinate at least 2wk before starting pertuzumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pirtobrutinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

influenza vaccine + pirtobrutinib

if possible, vaccinate at least 2wk before starting pirtobrutinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• polatuzumab vedotin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

influenza vaccine + polatuzumab vedotin

if possible, vaccinate at least 2wk before starting polatuzumab vedotin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pomalidomide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

pomalidomide

1 interaction

Monitor/Modify Tx

influenza vaccine + pomalidomide

if possible, vaccinate at least 2wk before starting pomalidomide tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponatinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ponatinib

1 interaction

Monitor/Modify Tx

influenza vaccine + ponatinib

if possible, vaccinate at least 2wk before starting ponatinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponesimod
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ponesimod

1 interaction

Monitor/Modify Tx

influenza vaccine + ponesimod

if possible, vaccinate at least 2wk before starting ponesimod tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisolone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

prednisolone

1 interaction

Monitor/Modify Tx

influenza vaccine + prednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

prednisone

1 interaction

Monitor/Modify Tx

influenza vaccine + prednisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• procarbazine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

procarbazine

1 interaction

Monitor/Modify Tx

influenza vaccine + procarbazine

if possible, vaccinate at least 2wk before starting procarbazine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• regorafenib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

regorafenib

1 interaction

Monitor/Modify Tx

influenza vaccine + regorafenib

if possible, vaccinate at least 2wk before starting regorafenib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• retifanlimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

retifanlimab

1 interaction

Monitor/Modify Tx

influenza vaccine + retifanlimab

if possible, vaccinate at least 2wk before starting retifanlimab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• revumenib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

revumenib

1 interaction

Monitor/Modify Tx

influenza vaccine + revumenib

if possible, vaccinate at least 2wk before starting revumenib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rilonacept
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

rilonacept

1 interaction

Monitor/Modify Tx

influenza vaccine + rilonacept

if possible, vaccinate at least 2wk before starting rilonacept tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rilzabrutinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

influenza vaccine + rilzabrutinib

if possible, vaccinate at least 2wk before starting rilzabrutinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ripretinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ripretinib

1 interaction

Monitor/Modify Tx

influenza vaccine + ripretinib

if possible, vaccinate at least 2wk before starting ripretinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• risankizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

risankizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + risankizumab

if possible, vaccinate at least 2wk before starting risankizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ritlecitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ritlecitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + ritlecitinib

if possible, vaccinate at least 2wk before starting ritlecitinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rituximab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

rituximab

1 interaction

Monitor/Modify Tx

influenza vaccine + rituximab

vaccinate at least 4wk before starting rituximab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• romidepsin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

romidepsin

1 interaction

Monitor/Modify Tx

influenza vaccine + romidepsin

if possible, vaccinate at least 2wk before starting romidepsin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ropeginterferon alfa-2b
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ropeginterferon alfa-2b

1 interaction

Monitor/Modify Tx

influenza vaccine + ropeginterferon alfa-2b

if possible, vaccinate at least 2wk before starting ropeginterferon alfa-2b tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rozanolixizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

rozanolixizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + rozanolixizumab

if possible, vaccinate at least 2wk before starting rozanolixizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rucaparib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

rucaparib

1 interaction

Monitor/Modify Tx

influenza vaccine + rucaparib

if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ruxolitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ruxolitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + ruxolitinib

if possible, vaccinate at least 2wk before starting ruxolitinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sarilumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sarilumab

1 interaction

Monitor/Modify Tx

influenza vaccine + sarilumab

if possible, vaccinate at least 2wk before starting sarilumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• satralizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

satralizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + satralizumab

if possible, vaccinate at least 2wk before starting satralizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• secukinumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

secukinumab

1 interaction

Monitor/Modify Tx

influenza vaccine + secukinumab

if possible, vaccinate at least 2wk before starting secukinumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• selinexor
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

selinexor

1 interaction

Monitor/Modify Tx

influenza vaccine + selinexor

if possible, vaccinate at least 2wk before starting selinexor tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• selumetinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

selumetinib

1 interaction

Monitor/Modify Tx

influenza vaccine + selumetinib

if possible, vaccinate at least 2wk before starting selumetinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sevabertinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sevabertinib

1 interaction

Monitor/Modify Tx

influenza vaccine + sevabertinib

if possible, vaccinate at least 2wk before starting sevabertinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sibeprenlimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sibeprenlimab

1 interaction

Monitor/Modify Tx

influenza vaccine + sibeprenlimab

if possible, vaccinate at least 2wk before starting sibeprenlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siltuximab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

siltuximab

1 interaction

Monitor/Modify Tx

influenza vaccine + siltuximab

if possible, vaccinate at least 2wk before starting siltuximab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siponimod
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

siponimod

1 interaction

Monitor/Modify Tx

influenza vaccine + siponimod

if possible, vaccinate at least 2wk before starting siponimod tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sirolimus

1 interaction

Monitor/Modify Tx

influenza vaccine + sirolimus

if possible, vaccinate at least 2wk before starting sirolimus tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus albumin-bound
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

influenza vaccine + sirolimus albumin-bound

if possible, vaccinate at least 2wk before starting sirolimus albumin-bound tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus topical
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sirolimus topical

1 interaction

Monitor/Modify Tx

influenza vaccine + sirolimus topical

if possible, vaccinate at least 2wk before starting sirolimus tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sorafenib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sorafenib

1 interaction

Monitor/Modify Tx

influenza vaccine + sorafenib

if possible, vaccinate at least 2wk before starting sorafenib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• spesolimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

spesolimab

1 interaction

Monitor/Modify Tx

influenza vaccine + spesolimab

if possible, vaccinate at least 2wk before starting spesolimab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sunitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sunitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + sunitinib

if possible, vaccinate at least 2wk before starting sunitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sunvozertinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

sunvozertinib

1 interaction

Monitor/Modify Tx

influenza vaccine + sunvozertinib

if possible, vaccinate at least 2wk before starting sunvozertinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tacrolimus
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tacrolimus

1 interaction

Monitor/Modify Tx

influenza vaccine + tacrolimus

if possible, vaccinate at least 2wk before starting tacrolimus tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tafasitamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tafasitamab

1 interaction

Monitor/Modify Tx

influenza vaccine + tafasitamab

if possible, vaccinate at least 2wk before starting tafasitamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• taletrectinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

taletrectinib

1 interaction

Monitor/Modify Tx

influenza vaccine + taletrectinib

if possible, vaccinate at least 2wk before starting taletrectinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• talquetamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

talquetamab

1 interaction

Monitor/Modify Tx

influenza vaccine + talquetamab

if possible, vaccinate at least 2wk before starting talquetamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tarlatamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tarlatamab

1 interaction

Monitor/Modify Tx

influenza vaccine + tarlatamab

if possible, vaccinate at least 2wk before starting tarlatamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teclistamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

teclistamab

1 interaction

Monitor/Modify Tx

influenza vaccine + teclistamab

if possible, vaccinate at least 2wk before starting teclistamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• telisotuzumab vedotin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

telisotuzumab vedotin

1 interaction

Monitor/Modify Tx

influenza vaccine + telisotuzumab vedotin

if possible, vaccinate at least 2wk before starting telisotuzumab vedotin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temozolomide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

temozolomide

1 interaction

Monitor/Modify Tx

influenza vaccine + temozolomide

if possible, vaccinate at least 2wk before starting temozolomide tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temsirolimus
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

temsirolimus

1 interaction

Monitor/Modify Tx

influenza vaccine + temsirolimus

if possible, vaccinate at least 2wk before temsirolimus start; otherwise, consider revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teplizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

teplizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + teplizumab

vaccinate at least 2wk before or 6wk after teplizumab tx: combo may result in inadequate vaccine response (immunosuppressive effects)

• teriflunomide
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

teriflunomide

1 interaction

Monitor/Modify Tx

influenza vaccine + teriflunomide

if possible, vaccinate at least 2wk before starting teriflunomide tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thioguanine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

thioguanine

1 interaction

Monitor/Modify Tx

influenza vaccine + thioguanine

if possible, vaccinate at least 2wk before starting thioguanine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thiotepa
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

thiotepa

1 interaction

Monitor/Modify Tx

influenza vaccine + thiotepa

if possible, vaccinate at least 2wk before starting thiotepa tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tildrakizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tildrakizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + tildrakizumab

if possible, vaccinate at least 2wk before starting tildrakizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tisagenlecleucel
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tisagenlecleucel

1 interaction

Monitor/Modify Tx

influenza vaccine + tisagenlecleucel

if possible, vaccinate at least 2wk before starting tisagenlecleucel tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tislelizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tislelizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + tislelizumab

if possible, vaccinate at least 2wk before starting tislelizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tocilizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tocilizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + tocilizumab

if possible, vaccinate at least 2wk before starting tocilizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tofacitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tofacitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + tofacitinib

if possible, vaccinate at least 2wk before starting tofacitinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• topotecan
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

topotecan

1 interaction

Monitor/Modify Tx

influenza vaccine + topotecan

if possible, vaccinate at least 2wk before starting topotecan tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• toripalimab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

toripalimab

1 interaction

Monitor/Modify Tx

influenza vaccine + toripalimab

if possible, vaccinate at least 2wk before starting toripalimab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• trabectedin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

trabectedin

1 interaction

Monitor/Modify Tx

influenza vaccine + trabectedin

if possible, vaccinate at least 2wk before starting trabectedin; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tralokinumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tralokinumab

1 interaction

Monitor/Modify Tx

influenza vaccine + tralokinumab

if possible, vaccinate at least 2wk before starting tralokinumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• trastuzumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

trastuzumab

1 interaction

Monitor/Modify Tx

influenza vaccine + trastuzumab

if possible, vaccinate at least 2wk before starting trastuzumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tremelimumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

tremelimumab

1 interaction

Monitor/Modify Tx

influenza vaccine + tremelimumab

if possible, vaccinate at least 2wk before starting tremelimumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• triamcinolone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

triamcinolone

1 interaction

Monitor/Modify Tx

influenza vaccine + triamcinolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• ublituximab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ublituximab

1 interaction

Monitor/Modify Tx

influenza vaccine + ublituximab

if possible, vaccinate at least 2wk before starting ublituximab tx: combo may result in inadequate vaccine response (immunosuppressive effects)

• upadacitinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

upadacitinib

1 interaction

Monitor/Modify Tx

influenza vaccine + upadacitinib

if possible, vaccinate at least 2wk before starting upadacitinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ustekinumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ustekinumab

1 interaction

Monitor/Modify Tx

influenza vaccine + ustekinumab

if possible, vaccinate at least 2wk before starting ustekinumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vamorolone
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

vamorolone

1 interaction

Monitor/Modify Tx

influenza vaccine + vamorolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids: combo may result in inadequate vaccine response (immunosuppressive effects)

• vandetanib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

vandetanib

1 interaction

Monitor/Modify Tx

influenza vaccine + vandetanib

if possible, vaccinate at least 2wk before starting vandetanib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vedolizumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

vedolizumab

1 interaction

Monitor/Modify Tx

influenza vaccine + vedolizumab

if possible, vaccinate at least 2wk before starting vedolizumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• venetoclax
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

venetoclax

1 interaction

Monitor/Modify Tx

influenza vaccine + venetoclax

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinblastine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

vinblastine

1 interaction

Monitor/Modify Tx

influenza vaccine + vinblastine

if possible, vaccinate at least 2wk before starting vinblastine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vincristine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

vincristine

1 interaction

Monitor/Modify Tx

influenza vaccine + vincristine

if possible, vaccinate at least 2wk before starting vincristine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinorelbine
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

vinorelbine

1 interaction

Monitor/Modify Tx

influenza vaccine + vinorelbine

if possible, vaccinate at least 2wk before starting vinorelbine tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• voclosporin
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

voclosporin

1 interaction

Monitor/Modify Tx

influenza vaccine + voclosporin

if possible, vaccinate at least 2wk before starting voclosporin tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zanidatamab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

zanidatamab

1 interaction

Monitor/Modify Tx

influenza vaccine + zanidatamab

if possible, vaccinate at least 2wk before starting zanidatamab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zanubrutinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

zanubrutinib

1 interaction

Monitor/Modify Tx

influenza vaccine + zanubrutinib

if possible, vaccinate at least 2wk before starting zanubrutinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zenocutuzumab
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

zenocutuzumab

1 interaction

Monitor/Modify Tx

influenza vaccine + zenocutuzumab

if possible, vaccinate at least 2wk before starting zenocutuzumab tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ziftomenib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

ziftomenib

1 interaction

Monitor/Modify Tx

influenza vaccine + ziftomenib

if possible, vaccinate at least 2wk before starting ziftomenib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zongertinib
FluLaval (influenza A and B trivalent vaccine, inactivated (IIV3))

+

zongertinib

1 interaction

Monitor/Modify Tx

influenza vaccine + zongertinib

if possible, vaccinate at least 2wk before starting zongertinib; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)